Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Samarium Sm-153 Lexidronam + Docetaxel in mCRPC
NCT00121095Phase 2Unknown
- Sponsor
- Cytogen, Inc.
- Start
- Jul 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of samarium-153 lexidronam in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Cytogen, Inc. Primary endpoint: Safety and tolerability of the combination treatment. Status: unknown.
02
Drugs
samarium-153 lexidronam
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT00121095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00121095.